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Abstract
This  chapter  provides  a  broad  overview  of  therapies  for  substance  abuse.  These
therapies are understood in the context of the history of drug use in the United States
and factors that influenced the expansion and regulation of substance use.  This is
followed by a discussion of how the complexity of these factors was associated with
difficulties in understanding substance misuse and created challenges to the creation of
effective treatment systems.  The chapter reviews the moral  and disease models of
addiction before discussing the diagnosis of substance-related disorders. The chapter
describes major treatment approaches and their efficacy.
Keywords: Substance abuse, Treatment
1. Introduction
This chapter will provide a brief overview of the history of substance abuse therapeutics and
survey of approaches to the treatment of substance use disorders. To fit the history of, and
approaches to, substance abuse therapeutics into a chapter of this type, great simplification is
required; at the same time, the entire enterprise bears much resemblance to the well-worn parable
of the group of blind men attempting to describe an elephant. The elephant parable illustrates
beautifully that reasonable people may disagree vigorously about the essence of something by
virtue of how they encounter it. This array of views has been likened to metaphors [1], but the
significance of each metaphor has profound implications. So, while the parable of the men and
the elephant does highlight the potential validity of differing perspectives on substance use, the
parable does not do enough to consider the implications and consequences of substance abuse.
Community and professional responses to substance use have reflected the untold conflict and
enormous consequences that have still  not yielded widely agreed upon responses to the
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destructive effects of substance use. The vast social issues include, but are certainly not limited
to moral, legal, ethical, economic, political, sociological, and psychological considerations. So,
it is virtually impossible to be exhaustive in one’s review of these issues, and this chapter will
focus only on the highlights of treatment of substance use conditions.
Modern data indicate that substance use and misuse continue to be widespread [2]. For 2014,
nearly 140 million people over the age of 12 used alcohol, more than 60 million reported some
binge drinking, and more than 16 million people reported heavy binge drinking in the United
States. Estimates for the use of illicit drugs overall appear to be overshadowed by data
pertaining specifically to marijuana use. More than 22 million people reported use of mari‐
juana, nearly 67 million reported use of tobacco, and more than 4 million persons reported
misuse of prescription medication. Perhaps of greater concern than the reported patterns of
use overall is the reported 17 million people whose self-reported use is consistent with a
diagnosis of an alcohol use disorder and more than 21 million people whose self-reported use
is consistent with a diagnosis of a substance use disorder. Clearly, misuse of psychoactive
substances remains a significant problem.
2. Early roots of treatment in the United States
The treatment of substance-related problems in the United States came from the intersection
of various forces in the middle of the nineteenth century. Patterns of alcohol and other
substance use, social reform movements, regulatory efforts, and the dynamics of professio‐
nal guilds all combined to shape the beginning of attempts to intervene with these problems.
Both the Europeans on the North American continent and the Africans who were brought as
slaves were users of alcohol, but the Native Americans were mostly not users of alcohol.
Cultural factors were significant and patterns of usage and resulting problems, including the
catastrophic effect of alcohol on Native American tribes [3]. As colonization progressed, public
drunkenness may have been the most significant problem that was explicitly identified [4].
Benjamin Rush (1746–1913) was an influential writer on a number of subjects, having been a
member of the Continental Congress, a signer of the Declaration of Independence, and notable
hospital reformer of the eighteenth century. Rush’s work was rich with descriptions of alcohol
use as a progressive medical condition that required abstinence as a method of invention. Until
the influence of his writings, alcohol had previously been seen as a moral problem or a
manifestation of mental illness [4].
2.1. Temperance
The American temperance movement emerged as alcohol-related problems became more
salient. As one might discern from the name of the organizations (“Temperance”), the initial
goals were to promote moderate use. However, the goals of the temperance movement
changed to a perspective that emphasized abstinence [5]. While modern abusers of substan‐
ces must battle for recovery in the context of a variety of possible interventions, substance
abusers in the nineteenth century had far fewer alternatives. There is evidence that these
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persons turned to a variety of social change movements and were met with various attitudes.
For example, the political attitudes of temperance movement participants could sometimes be
confused with other political stances (e.g., slavery). Thus, factors that were associated with the
rise and fall of various social movements were also critical to attempts to establish programs
to assist substance users (primarily alcoholics at that time).
2.2. Institutional treatment
Because of the difficulties associated with substance misuse, attempts have been made to
provide shelter for persons who needed some form of assistance. These efforts to provide
residential care have been referenced in writings as long as 5000 years ago [6]. By the early
1800s in the United States, the physical effects of alcohol were becoming clearer, and there was
a significant increase in the number of institutions that emphasized the treatment of alcohol
and other addictions [7].
Just as the public response to substance abuse was a product of complex forces, complex forces
were also significant to treating institutions. Economic forces, primitive clinical methods,
conflict within the field, and problems associated with individual behavior all contributed to
a decline in the institutional treatment movement. It was clear by the mid-1800s that the search
was on for more effective approaches to treating addictions. Not surprisingly, miracle cures
were suggested in the context of entrepreneurialism. Innumerable chemical preparations and
marketing techniques were seen [8]. The first “inebriate asylum” was called for by Dr. Samuel
B. Woodward, whose efforts led to the establishment of the first real institutional treatment in
the form of the New York State Inebriate Asylum, established in 1864. The first facility for
women was the Martha Washington Home in Chicago that was established in 1867. Further
progression in institutional care as part of the moral treatment that Dr. Woodward espoused
was slow to grow.
2.3. The increase in legal controls
The sentiment of many Americans seemed to have been critical of the non-medical use of any
drug, including alcohol and tobacco. From colonial times through the Civil War, these attitudes
were associated with abstentionist outcries against alcohol and tobacco and calls for regula‐
tion. The regulation of substance use has been increasingly relevant to treatment since the
proliferation of public regulations in the early 1900s. However, the energy expended to stem
the availability and use of psychoactive substances has met with controversy. The specific
consequences of both direct and indirect action included the intention to eliminate use,
pressure to make the price of substances rise, and efforts to reduce social costs of use [9].
History has been clear that race, ethnicity, and social class have been highly tied to efforts to
control substance use and that legal controls frequently represented bigotry and oppression
that served the aims of dominant groups.
The path to regulation began with registration and taxation mandates. The first significant step
in this regard was the Pure Food and Drug Act of 1906. At time in which there had been decades
of proliferation of substances and their combination in Patent Medications, the Pure Food and
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Drug Act established the requirement that medications with opiates and other drugs must
provide a list of ingredients. This made opium and cocaine were early casualties of regula‐
tion attempts [10].
The Harrison Narcotic Act was passed in 1914 by the United States government. The origi‐
nal intention of the bill was to place a special tax on opium and coca, but the effect was to
eliminate legal opiates. Alcohol and tobacco were also soon to be subject to growing legal
pressure. Tobacco was not traditionally used in the form of modern cigarettes, but tobacco
habits were fostered by the development of modern cigarettes, leading to large increases in
tobacco use between 1900 and 1910.
The battle over alcohol was even to be more visible and controversial. Andrew Volstead of
Minnesota saw his name attached to the Eighteenth Amendment to the United States
Constitution. The result of the “Volstead Act” (H.R. 6810) was that from 1920 until 1933, and
the manufacture, sale, and consumption of alcohol were prohibited in the United States. The
failure of prohibition leads to the Twentieth Amendment that repealed federal prohibition
in 1933. The states gradually repealed their own legislation ending with Mississippi in 1966.
As one alternative to the futility of broad prohibition, legally mandated treatment for substance
abusers is now widely practiced [11], and legally mandated treatment is seen as a sensible
approach for persons whose criminal offense is substance related. The intention is to direct the
convicted individual to a system in which treatment is a more central focus then would be
expected in a traditional correctional context. Critics of the approach question the propriety
and efficacy of this strategy.
2.4. Spiritual traditions and intervention
Another common perspective on treatment of substance-related problems emerged from
spiritual traditions. Spiritual traditions provided the foundation for a variety of approaches to
substance-related problems. Some of this influence has been direct and some indirect. For
example, a movement as broad as the American temperance movement was substantially
derived from the evangelical movement. The Benjamin Rush speculated that religion by itself
could “carry the day” with substance abusers [12]. The early view that religious experiences
were an important path to recovery was bolstered by the perspectives of some early mental
health professionals. Some professionals in health care were skeptical of religious ap‐
proaches and others opined that religious approaches were only good for certain patients. Even
within psychology, there were advocates for spiritually based intervention. The prominent
work of George Cutton’s The Psychology of Alcoholism (1907) and the broad work of the
pragmatist William James (non-practicing M.D. and Harvard psychologist) went far to
legitimize the spiritual view. James was well known because of the variety of his contribu‐
tions related to psychology. James operationalized the center of religious conversion as anti-
Christian by referring to it as “the hot place in a person’s consciousness … The habitual center
of one’s personal energy ([13], p. 196).” Despite knowing that reports of religious conversion
experiences would be met with skepticism in a professional community of materialists, James
felt that the results or specific components of spiritual interventions should be considered
independent of the underlying assumptions of a particular spiritual perspective. The contin‐
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ued significance of the spiritual contribution to substance abuse therapeutics is reflected in a
number of contemporary realities. The United States Congress passed a measure in 1996 that
allowed states to contract with faith-based programs in substance abuse treatment. This led to
an increase in emphasis on such programs and associated research into the effectiveness of
such approaches [14, 15]. Typically, such programs include Bible study, church services,
spiritually based therapy, in addition to a strict regimen of activities. There are continued
efforts to clarify the precise nature of treatment that is based on Christian principles [16].
3. Models of misuse and methods of treatment
3.1. The diversification of substances
Many types of substances have been used throughout history for a host of purposes. Early
North American settlers used a variety of preparations for a variety of medicinal and recrea‐
tional purposes. Until the late 1800s, it was easy for opponents of substance use to locate their
targets. Many substances began as legitimate medications and became used outside the clinic.
Despite the widespread use of a variety of substances, it was not until the Controlled Substance
Act of 1970 that anti-substance law began to keep up with the great variety of substances that
are used. The proliferation and diversification of substance use, the variety of substance
pharmacologic action, the impact of route of administration, and the host of socio-cultural
factors have all been significant in the development of effective treatment methods [17].
Tobacco was first introduced to Europeans by Native Americans. Sailors adopted tobacco, both
smoking the leaf and chewing it and brought tobacco home to Europe. By the time of the Civil
War, alcohol and tobacco were established and clearly the most common American substan‐
ces associated with problematic use.
Marijuana use has a long and complex history. Varied types of cannabis existed long before
its appearance in the United States. Cannabis sativa was available in the early days of the new
world, first appearing in South America in the 1500s [16]. Varieties of cannabis were both a
medicinal/recreational substance and a critical crop for the American colonies in the 1700s.
Hemp was grown for its fiber, and it was a major export for farmers as well as a source of rope
and sail material. In the 1800s, hemp plantations thrived in Staten Island, New York, as well
as in Mississippi, Georgia, California, South Carolina, and Nebraska [17].
At the same time that Hemp was so commercially and strategically significant, cannabis sativa
was becoming better known. Cannabis was known to have been used for thousands of years
in China, and “marijuana” became a widely accepted medication in the nineteenth century.
Limited non-medical use of cannabis began to appear and the allegedly scandalous behavior
of cannabis users was a featured item in the popular press in the early decades of the 1900s [17].
Publicity associated with anti-cannabis sentiments demonized the substance and patterns of
its use and manifest subtle themes of bigotry against Mexican people.
Opium was a new entry to the American scene in the 1800s. Railroad laborers from China
brought their opium smoking habit with them as they were hired by railroad magnates as less
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expensive labor than Americans. The connection between opium and the displacement of
American workers was not to be forgotten and became a part of legislation that emerged later.
However, the use of opium was not regulated by the mid-1800s, so opium and its extrac‐
tions were readily available. For medical purposes, morphine had been derived from opium
in the early 1800s and became an ingredient in some patent medicines (discussed below) in
the United States. A vibrant patent medicine industry developed in the United States, with
widespread marketing and distribution of a many products that contained large quantities of
opium. These “medicines” claimed to cure just about anything, but they were really a vehicle
for opium at an inexpensive price [17]. Perhaps, the most commercially dramatic develop‐
ment among the opioids was heroin. The Bayer Company first marketed heroin in 1898 as
an (allegedly) addiction-free pain medication as well as a curative for abuse of other opioids.
Cocaine has a long history that first appeared in accounts of the chewing of coca leaves by the
native populations of South America [17]. By 1844, cocaine had been isolated in pure form,
though little use of it was made until later in the century. In the late 1870s, cocaine was used
for the treatment of alcoholism and morphine addiction. In the 1880s, Sigmund Freud became
aware of the use of cocaine to sustain Bavarian soldiers and started to experiment himself. He
published his exuberance quickly, but he came to see cocaine as more problematic than he
originally reported. Other distinguished medical professionals saw cocaine’s beneficial
potential. William Stewart Halstead found the mood enhancing and anesthetic properties of
cocaine in the mid-1880s.
Amphetamines were first created in the laboratory in 1887, but it took 40 years for clinical
applications to be realized. Military physicians used these stimulants for various purposes in
the combat theater as well as in clinics. Illicit use increased in the military in the 1950s [17],
and the use was also seen in truck drivers and students for a variety of medical conditions.
By the 1870s, Native Americans had begun ritual use of peyote, as had the Aztecs before them.
For the Comanches, Cheyennes, Arapahoes, and other tribes, peyote rituals were a complete‐
ly religious practice, requiring total abstinence from alcohol. Among these tribes, alcohol was
considered to be a substance of considerable abuse. White land speculators sought to have
peyote outlawed as a way to join with Christian missionaries and secure the Indian land. Much
like other pursuits of criminalization of substances, there was a powerful motive that was
different than the overt motivation [17].
As existing medications took more complex and pure forms, there was an increase in the
promotion of “patent medicines.” These preparations were promoted with great vigor, so had
creative names and claims of effectiveness that were more associated with marketing than
clinical effect. These preparations that were not actually patented were produced in England
and began to appear in the colonies in the 1700s. The production of patent medications grew
independently in the United States in the nineteenth century and was available through a wide
range of vendors. Alcohol, cocaine, and morphine were common ingredients [18, 19]. These
products included Laudanum (an alcohol preparation that originally included all of the opium
alkaloids), Vin Mariani (a wine with coca leaves), and Coca-Cola (with cocaine as an ingredi‐
ent).
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In 1943, Dr. Albert Hofmann discovered what came to be a popular and widely used halluci‐
nogen, lysergic acid diethylamide (LSD). Working with the fungus ergot to isolate compo‐
nents for pharmaceuticals, he accidentally ingested a small amount of the substance and had
what has been described as the “first acid trip.” Despite his careful account of the experience
in a professional publication [20], his serendipitous discovery has been widely repeated and
distorted. Hofmann went on to do further research in several areas and was persistent
throughout his career in his criticisms of public claims of the great dangers of LSD.
3.2. Expanding treatment in the early twentieth century
Before the Second World War, there were relatively few treatment alternatives for a person in
trouble with substance use. Concerned persons and some healthcare professionals com‐
plained about the limited treatment options, but most addiction treatment centered on the
management of withdrawal symptoms (now known as detoxification). The result of the lack
of treatment was increased the expansion of where addicts would seek mood-altering
substances. The lack of treatment and expanding drug seeking combined with advancing
criminalization led to the evolution of a new category of criminal. In addition, the United States
Public Health Service became involved in the problem of addiction in the 1920s. State facilities
for psychiatric patients and prisons were being overcrowded because of the arrests follow‐
ing the Harrison Narcotic Act [17]. In 1929, the Porter Act was passed, allocating funds to
develop to rehabilitation facilities. The first results of this legislation were the new facilities in
Lexington, Kentucky (1935) and Forth Worth Texas (1938). Treatment consisted primarily of
withdrawal, convalescence, and rehabilitation. Outcome studies yielded disappointing
results.
Three groups were critical to the development of what has become known as the “modern
alcoholism movement.” The Research Council on Problems of Alcohol, the Yale Center of
Alcohol Studies, and the National Committee for Education on Alcoholism combined to
promote a host of initiatives aimed at promoting treatment [21]. Following the Second World
War, there was increasing understanding about substance abuse disorders and the need to
organize public health efforts. The “disease model” (discussed below) was instrumental in
promoting significant discussions about substance-related problems. Most treatment still
occurred in general hospitals, state psychiatric hospitals, and private sanitariums. It is also
significant that freestanding treatment programs began to appear. Many of the early free‐
standing programs became well known because of the unique ways in which they were
developed. What came to be important to all of the treatment efforts that began to emerge was
the nature of each facility’s connection to alcoholics anonymous.
3.3. Alcoholics and narcotics anonymous
Alcoholics anonymous was established in 1935, and the eponymously named book of the
central tenets of AA was published in 1939. AA is based on 12 “steps” that are central to the
process of recovery and are considered to be indispensable to success. These steps are part of
a program that is codified in the “Big Book” and is very specific about being effective for 75%
of the participants [21]. With an avowed spiritual foundation (e.g., Step 2: “Came to believe
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that a Power greater than ourselves could restore us to sanity” and Step 5: “Admitted to God,
to ourselves, and to another human being the exact nature of our wrongs”), AA developed a
strong following and claimed considerable success. When AA was established, the treat‐
ment industry and the understanding of addiction could reasonably describe as being in its
infancy. Despite claims made in the Big Book, the efficacy of AA is very difficult to submit to
rigorous empirical evaluation due to the structure and procedures of the organization [22].
As noted above, the range of substances used and the associated problems expanded in the
early twentieth century. Efforts to assist users of substances other than alcohol gradually
expanded. By the mid-1940s, AA’s co-founder Bill Wilson discussed the possibility of a group
for a drug addicts that was separate from AA.
The first realization of Wilson’s idea was called NARCO; it first appeared in 1947 and met
weekly at the United States Public Health Service’s treatment center in the Lexington,
Kentucky federal prison. By the end of the 1940s, a NARCO member started a short-lived group
called “Narcotics Anonymous” in the New York Prison System. By 1953, Narcotics Anony‐
mous was clearly established in California [17]. Early members, many of whom were from AA,
worked out the 12 Traditions for the new organization. Within a year, the first NA publica‐
tion was printed, called the “Little Brown Book.” There was controversy in AA and NA
regarding Bill Wilson’s experimentation with LSD. While he experimented under the super‐
vision of a psychiatrist and a psychologist, the use of another drug (in addition to alcohol) was
seen as antithetical to the letter and spirit of “Anonymous” teachings.
AA continues to foster a spiritual foundation and works to alter the thinking of alcoholics
through “spiritual awakening.” Studies of the effectiveness of AA have not produced clear
results. AA is supported primarily by voluntary donations, and meetings are held in a vast
array of facilities, including prisons, treatment facilities, hospitals, and churches. AA groups
are available in most towns in the United States. Despite the relative paucity of efficacy studies,
AA has been recognized by professional groups [21]. In addition, despite initial scorn by much
of the medical profession, the American Medical Society recommended use of such self-help
groups in 1979.
3.4. The moral and disease models
3.4.1. The moral model
Modern medical views of substance misuse claim to view the problem as a medical, rather
than moral, problem. This appears to refrain from giving serious consideration to morality or
values as the foundation for the problem. However, there is considerable evidence, in public
opinion and its reflection in political discourse and the law, that substance misuse continues
to be viewed as a moral problem. Consistent with current views, there is extensive history of
morality as a dominant component of the views of substance abuse by many [23]. The moral
view was, in part, a part of an absence of other useful perspectives. However, there is also
substantial evidence for social control exerted from class and culture-related factors [24, 25].
Social groups who were so oriented would promote public campaigns in which misinforma‐
tion and inflammatory information were promoted related to the types of substances used, the
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nature of substance use, and other conduct associated with substance use. Substance use and
certainly misuse was proclaimed to be a manifestation of misplaced values and lack of moral
standing. Today, criminal penalty remains a dominant approach to substance-related
problems, despite considerable evidence that argues against the practical value of such an
approach. Some elements of faith-related perspectives, while offering assistance to some users,
continue to communicate judgment of these problems.
3.4.2. The disease model
One of the most significant developments in the intellectual representation of substance use
disorders was the “Disease Model” of addiction. The first major proponent of this approach
was Morton Jellenik [26]. Jellinek had witnessed the massive failure of the Volstead Act to stem
the use of alcohol and began to write from the Yale Summer School of Alcohol Studies. The
Disease model posits that certain individuals are vulnerable to substance use disorders as a
result of (inferred) neurochemical dysfunction. This “disease” is characterized by, in part, an
inability to control/inhibit behavior, loss of control, a failure to recognize the syndrome in one’s
self, and predictable decline. The disease model also suggests that the substance abuse
vulnerability can/does occur independent of other problems and is chronic. Thus, the
enlightened practitioner refrains from judgment of the abuser, and problems with substance
use should be permitted to mitigate criminal punishment when crimes are committed [27].
The disease model is not always described in the same way, and it may be seen as having
evolved since its first description. For example, despite the focus on factors internal to the
substance abuser in the disease model, [28] characterized the disease model as being
“multidimensional” and including psychological and sociocultural factors.
The later diversification of the disease model has done little to mute its detractors. Major
objections to the disease model appear to be linked to the basic assumptions of any disease-
related approach. For example, Wallace [29] called for a move beyond the disease model in
the context of Native North Americans, suggesting that the disease model is particularly toxic
in its neglect of context and culture in evaluating and intervening with substance-related
problems. Feminist theorists have highlighted the construction of gender in the context of
research and treatment approaches in general [30]. A behaviorist approach has also made
cogent arguments against the disease model [31].
Recognizing the actual physical destruction that is a possible result of substance use, some
behaviorists argue that a disease model is not needed at all for there to be adequate rationale
for effective treatment. Consistent with general behavioral principles, the behavioral ap‐
proach finds it more useful and even humane to view the problematic use of substances is a
by-product of the interaction between unique features of virtual and reinforcement contin‐
gencies within their environment. That is, what is rewarding about the context in which a
person has learned to use the substance? The behaviorist perspective also gives careful
consideration to the nature of motivation, since the nature of motivation, or drive states, is
critical to the reward value of environmental features.
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3.5. Diagnosis of the substance-related disorders
The history of psychology and psychiatry includes a legacy of efforts to develop the most
elegant and powerful nosology of disorders of psychological adaptation. There is evidence of
attempts to categorize disorders as far back as the ancients, but increased focus emerged
around 1900 and has accelerated since. The first comprehensive modern work was the
Diagnostic and Statistical Manual (DSM) in 1952 [32]. Given that psychoanalysis still en‐
joyed hegemony in the clinical world of the late 1940s, the original DSM was relatively brief
and grounded in clinical lore and psychoanalytic theory. The DSM subsequently evolved from
a primarily psychoanalytic work to an atheoretical compendium that is designed to reflect the
highest levels of clinical and empirical science. By the time of DSM-II (1968 [33]), the role of
theory was substantially reduced and increasing specificity in diagnostic criteria was realized.
The introduction of the Diagnostic and Statistical Manual of Mental Disorders (Fifth edition:
DSM-V [34]) brought revisions to previous diagnostic criteria in the DSM tradition. Most
recently, the DSM-IV [35] used two main categories of substance misuse conditions, sub‐
stance abuse and substance dependence. The DSM-IV criteria were considered to be inade‐
quately descriptive of what was seen clinically, and the new criteria are claimed to be a
substantial improvement. These two categories from DSM-IV were combined into one
disorder in DSM-V that is diagnosed in conjunction with a rating from mild to severe. This
also eliminates the “substance dependence” category, which was widely seen as easily
confused with “addiction.” While using the same underlying criteria, each substance is
indicated as a distinct use disorder, including alcohol, cannabis, hallucinogens, inhalants,
opioids, sedatives, hypnotics or anxiolytics, stimulants, and tobacco. Caffeine-related syn‐
dromes are not included.
It is important to review the DSM-V criteria for substance use disorder. It is important to bear
in mind that each of these eleven criteria may be manifest in different ways and will be
influenced heavily by the pharmacology of the specific substance. For each of the substances,
the following are the eleven possible symptoms:
1. Taking the substance in larger amounts and for longer than intended
2. Wanting to cut down or quit but not being able to do it
3. Spending a lot of time obtaining the substance
4. Craving or a strong desire to use the substance
5. Repeatedly unable to carry out major obligations at work, school, or home due to
substance use
6. Continued use despite persistent or recurring social or interpersonal problems caused or
made worse by substance use
7. Stopping or reducing important social, occupational, or recreational activities due to
substance use
8. Recurrent use of substance in physically hazardous situations
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9. Consistent use of opioids despite acknowledgment of persistent or recurrent physical or
psychological difficulties from using substance
10. *Tolerance as defined by either a need for markedly increased amounts to achieve
intoxication or desired effect or markedly diminished effect with continued use of the
same amount (does not apply for diminished effect when used appropriately under
medical supervision).
11. *Withdrawal manifesting as either characteristic syndrome or the substance is used to
avoid withdrawal (does not apply when used appropriately under medical supervision).
The DSM-V section with substance-related disorders includes gambling, which was not in the
same section as substances in prior versions of DSM. The task force members for the sub‐
stance and other addictive disorders section gathered findings that suggest that gambling
disorder is similar in a number of respects to substance-related disorders. It is also thought
that this development will make the accessing of treatment more likely. Other disorders that
may be considered relevant (e.g., Internet, social media) have not yet been seen as having the
empirical support needed for inclusion in this section.
4. Treatment approaches
There have been a staggering number of treatment approaches substance-related problems
over the centuries [17]. It is virtually impossible to organize and categorize all treatment
approaches, and the intersection of treatment method and type of professional further
complicates the picture. The difficulties of professional domains and perspectives are further
exacerbated by the relative lack of evidence for the effectiveness for different interventions
[36]. In fact, there is some evidence to suggest that the specific treatment approach or techni‐
que is not as important to outcome as are factors associated with intervention relationships
such as empathy [37]. Garner [38] issued a clear call for greater methodological rigor in studies
of treatment efficacy to ensure development of treatment approaches that are grounded in
empirical support. Recent suggestions have begun to clarify how this research might be
conducted. DuPont et al. [39] suggested that addiction should be considered separate from
other forms of health care because of the complexity and need for better kinds of research. In
addition, they highlighted the high level of investment required in successful treatment, the
variety of substances associated with disorders, and the varieties of organizational struc‐
tures present in the treatment community. They also highlighted the severity, complexity, and
chronicity of these disorders as important guideposts for the development of outcome
measures. In light of the complexity of the treatment factors just noted, the final section of this
chapter will highlight a few of the major treatment perspectives.
4.1. Detoxification
The critical role of detoxification in substance abuse treatment has continued since its central
place in nineteenth century treatment. Because of a relative lack of knowledge about the exact
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impact of substance use, addictive processes, and treatment, there was obvious emphasis
detoxification as an essential step in recovery. In addition, there was considerable emphasis
on physical dependence as a central element of addiction. So, work with a patient began with
simply clearing the body of the toxic substances, often with inpatient medical supervision and
sometimes medications such as benzodiazepines. Today, detoxification is not technically
considered to be actual treatment for a substance use disorder, though it is widely seen as a
fundamental first step for treatment. However, contemporary perspectives on treatment
manifest great variability in the rate of movement from detoxification to longer forms of
intervention. The relative merits of gradual versus sudden withdrawal quickly became a
matter of intense dispute in the medical community [1,42–44]. Modern research has identi‐
fied factors that make detoxification a more effective part of a treatment system in which
approximately one-fifth of annual admissions include detoxification [40]. The availability of
intervention beyond detoxification is greatly influenced by healthcare economics. Despite
efforts associated with the Affordable Care Act, many persons with substance use disorders
are uninsured or underinsured. It is clear that finances are associated with the quality of
intervention as well as limitations on the quantity and nature of service modalities. The
Wellstone and Domenici move in 2008 to bring parity to mental health care did attempt to
reduce barriers to treatment utilization, reduce financial burdens, and decrease stigma, though
the success of those efforts is a matter of debate [41].
4.2. Harm reduction
“Harm reduction” is a relatively recent approach that functions in contrast to abstinence-only
models. There have been several major contributors who have influenced this approach,
though their assumptions and strategies are similar (in particular [1, 42–44]. With a pragmat‐
ic perspective that is theoretically inclusive, the harm reduction approach considers psycho‐
active substance use to be a part of the human experience and works to minimize damage
resulting from use. The harm reduction approach, like many other approaches, considers
substance use (and misuse) to be a complex result of many forces and maintains the view that
there are constructive and destructive ways to use many substances. Without minimizing the
real destruction from use, this perspective emphasizes the participation of substance users in
reducing harm as well as the great significance of poverty, class, racism, social isolation, past
trauma, sex-based discrimination and other social inequalities as vulnerability factors. With
this broad emphasis, intervention is associated with the unique realities of the person who is
struggling with substances and predetermined treatments are not embraced. Proponents of
harm reduction thus characterize it as a public health alternative to moral, criminal, or disease
models. From this point of view, it is appropriate to adopt a “whatever it takes” perspective
on intervention with persons who abuse substances.
Peele, in particular, supports harm reduction and speaks in contrast to the AA tradition,
promoting natural solutions in the context of careful goal-setting and the making of person‐
al meaning in recovery. His writing includes specific arguments about the perils of the disease
model. Peele argues that addicts are not different from other people in respects other than the
addiction. In addition, Peele disputes a number of long-standing assumptions of the AA
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tradition. He does not agree that recovery depends on forces outside the individual or that
substance abusers are unable to control themselves in any situation. Since Jellenik’s seminal
contributions to the disease model, “addiction” has been perceived as a predictable, progres‐
sive, and fatal disease. Peele argues that this is not the standard progression through which
an addict must inexorably pass, and recovery does not consist of a lifelong conscription to
absence and twelve-step methods. In fact, Peele argues that the pessimism and determinism
that are intrinsic to the disease model actually contribute to the likelihood of relapse and
continued harm.
Some harm reduction techniques include methadone maintenance, which serves as a safer
alternative to heroin use because of the longer half-life of methadone and the safer route of
administration. Other approaches may include over the counter medications or even care in
maintaining hydration with club drugs [45]. Needle exchange programs have been a highly
visible and controversial approach to harm reduction that targets the high levels of risk
associated with sharing intravenous drug administration supplies [46].
The harm reduction approach has been bolstered by the addition of mindfulness techniques
[47]. Grounded in Buddhist tradition, mindfulness is considered to be the cultivation of
awareness in the present moment. Mindfulness practices have been integrated into many of
the therapeutic approaches since it began to appear in Western teachings in the 1950s.
Mindfulness began to appear into the scientific literature associated with substance abuse
treatment relatively recently [48].
4.3. Relapse prevention
“Relapse” refers to a return of problem behavior following an interval during which an
individual has been relatively problem free. The study of relapse has been motivated by the
prevalence of relapse, by attempts to bolster treatment effectiveness as well as to understand
the persistence of substance-related problems. The practice of relapse prevention is an eclectic
blend of a variety of approaches that have mixed empirical support. Many of these ap‐
proaches are rooted in clinician beliefs and experience as well as guidance from recovering
users. For example, “booster sessions” may follow the termination of regular treatment contact.
Relapse prevention strategies are likely to be a part of a final phase of treatment and at‐
tempts to solidify relapse prevention may be a routine protocol during a termination phase.
Recovering users are called upon to identify high risk situations and develop a range of robust
coping mechanisms. Similar to this evaluation of the environment, persons in the treatment
are encouraged to identify warning signs within him or herself as well as overall factors of
vulnerability that may increase the risk of relapse. Attempts to generalize training experien‐
ces that are cultivated in treatment include exercises to bring lessons from treatment to real-
life situations.
4.4. Interpersonal therapies
Since the inception of psychoanalysis in the late 1800s, the relationship between a would-be
healer and a suffering person has been considered to be critical to the success of interven‐
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tions. As the understanding of the fundamental conditions of therapeutic relationships
advanced in the twentieth century, so did empirical support for the essential quality of certain
therapeutic conditions. Interpersonal therapies were not initially designed for substance
abusing persons, and the psychopharmacology of substances was recognized early in the
history of psychotherapy as a complicating factor in treatment. Freud’s exaltation of and
subsequent struggle with cocaine is a well-known example of this uncomfortable reality. Early
psychoanalytic theories of substance misuse were provocative and controversial [49–52]. In
general, however, themes emerged that suggested that substance use problems developed in
association with the person’s inability to meet their inner needs in more adaptive ways [53].
Interpersonal approaches to substance use disorders are optimized when recognizing and
incorporating psychopharmacological and substance use realities. In addition to the realities
of substance misuse, patients are encouraged to confront issues that emerge in the absence of
the substances. For example, a recovering user may be encouraged to grieve the “lost friend”
of the substance. Shame is frequently identified and challenged as a factor in the inevitable
frustration of needs. Defense mechanisms, originally couched in psychoanalytic language as
negative factors, became seen as essential elements of psychic life and forces which need to be
improved and not eliminated. For persons who use substances in problematic ways, defense
mechanisms are identified as adaptive or maladaptive and modified accordingly. In general,
the enhancement of self-expression and the relative satisfaction associated with human
connections are bolstered in this approach.
4.5. Cognitive behavior therapy
Cognitive behavior therapy (CBT) may reasonably consider one of the dominant perspec‐
tives in mental health and substance abuse therapeutics today [54]. CBT is a blend of behav‐
ior therapy (BT) and cognitive therapy (CT). BT was originally introduced as an attempt to
apply laboratory-based behaviorism to human change processes. BT was, in part, a reaction
to psychoanalysis that was seen as pessimistic, deterministic, and nearly impossible to
investigate empirically. An example of a behavioral approach to substance abuse therapeu‐
tics is contingency management (CM[55, 56]). CM uses the principles of operant condition‐
ing and provides established reinforcers for drug abstinence or other objective measures of
drug abstinence. The rewards may be a coupon for goods and services, a verbal reward, or
small monetary tokens. This approach includes escalating rewards with rules for resetting the
reward when there has been a relapse. Another example of a behavioral approach illustrates
the role of contingencies on task participation (in contrast to abstinence as in the previous
example). Spohr et al. [57] reported the results of behavioral approach in which rewards were
established related to participation in probation and treatment of tasks.
Cognitive therapy has a broad history, in as much as there is evidence of some of the central
tenets of the approach in the writings of the ancients [54]. While there are an increasing number
of variants, cognitive therapy addresses thinking patterns that contribute to problems in
adaptation.
Another approach that some consider to be within the cognitive behavioral tradition is
dialectical behavior therapy (DBT [58]). DBT is an empirically supported therapy approach
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that was designed originally to assist persons who are struggling with symptoms of border‐
line personality disorder. Since its original development, it has been adapted for the treat‐
ment of substance use disorders [59]. DBT prioritizes risky behaviors (self-injury) and then
works directly with substance use issues. Next, the approach attends to effects of substance
use, such as legal jeopardy and vocational difficulties. Finally, DBT builds skills for broad
psychological adaptation and relapse prevention.
4.6. Contributions from contemporary pharmacology and neuroscience
With the rise of neuroscience and a deeper understanding of cognitive processes, contempo‐
rary neuroscience has begun to offer evidence holds some promise of informing clinical efforts.
It has been suggested [60] that mechanisms associated with motivation and control elements
of addictive processes are better illuminated by advances in the neurocognitive laboratory than
prior models. In particular, attentional bias, reward processing, and cognitive control are
important areas of research that are soon to make direct contributions to treatment. These
findings are consistent with early findings related in impulse control that indicate that impulse
control problems is a likely culprit in at least the exacerbation if not a cause of substance abuse
problems [61]. EEG study has suggested that patterns of substance misuse may be associat‐
ed with detectable deflections in brain activity as assessed via quantitative electroencepha‐
lography (qEEG) methods [62]. The decade of the 2000s reflected increased interest in the role
of executive function in a number of human problems in adaptation including substance abuse
patterns. An essential element of executive function is the capacity to postpone, prevent, and/
or arrest a behavioral response to permit time for the development of more constructive paths
of behavior [63].
Some facets of substance misuse phenomena are being treated with repetitive transcranial
magnetic stimulation (rTMS [64]). This non-invasive method uses an electromagnetic field that
changes rapidly and induces electrical currents in the brain. rTMS has been found to have
promising effects on some aspects of addiction-related cognitions. While there is continued
investigation into the exact mechanism of effect of rTMS, craving has been seen as an area of
patient difficulty that responds to rTMS [65].
The role of dopamine represents another avenue of research/treatment progress. While the
direct treatment implications are not clear, it is important to note that the emerging work in
physiology indicates that substance abuse and disinhibition are different [66]. Prominent
striatal dopamine has an important influence on externalizing proneness (disinhibition) and
on reward-based decision-making. Using eyeblink rate as estimator of dopamine level
associated with disinhibition, investigators have found that dopamine is more strongly
associated how much an individual “wants” (motivation) to learn about making decisions
associated with tangible rewards. This orientation to learning about decision-making is then
accompanied by working with an individual’s broader substance use patterns that are
associated with learning of action-reward contingencies [67].
For a number of reasons consistent with the approaches just noted, psychotropic medica‐
tions have been used with some success to reduce vulnerabilities associated with substance
misuse syndromes. Medication-assisted treatment (MAT) uses medications that can reduce
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cravings (agonists or partial agonists), interfere with the pleasurable sensations that come from
use (antagonists), or create negative feelings with a substance is taken. Methadone, buprenor‐
phine (opioid partial agonist-antagonist), and naltrexone (antagonist) have been used for
opioid addiction. Antabuse has been used for alcohol since tire manufacturers noticed that
workers could not drink alcohol after the vapors of the precursor of antabuse was inhaled
during the vulcanization of rubber [17]. In the wake of problems associated with methadone
maintenance, buprenorphine has become an effective alternative in reducing withdrawal
symptoms and cravings associated with opioid dependence. For nicotine, there are three FDA-
approved approaches to nicotine replacement. The FDA first approved nicotine gum
(approved in 1984 and available over the counter in 1996) and the transdermal nicotine
patch (approved in 1992 and over the counter in 1996) for smoking cessation. Finally, nicotine
sprays (1996) and inhalers (1998) were approved for dispensing by prescription. Other
psychotropic medications have been used in an off-label fashion to reduce depression and
anxiety associated with recovery.
4.7. Motivational interviewing
Motivational interviewing (MI) is defined by its originators as a directive, client-centered
counseling style for eliciting behavior change by helping clients to explore and resolve
ambivalence [68]. The developers of MI affirm that MI is primarily a style of relating to service
recipients rather than a specific set of techniques [69]. The originators of MI explicitly described
borrowing many ideas from the interpersonal therapy tradition, and MI has become a “Gold
Standard” for intervention. MI concepts include a focus on the capacities of the client,
maintaining positive communication, an emphasis on resolving change-related ambivalence,
and appreciating the variability in change readiness. In addition, empathy is emphasized and
therapeutic resistance is a force with which one collaborates, and client inconsistencies are
challenged. Further, MI emphasizes engagement with clients in empathic and collaborative
communication, attention to established behavior change goals, and the initiation of change
planning when the client is ready. There is a growing body of empirical work that supports
the efficacy of MI for substance abuse disorders [70, 71].
Despite the fact that MI is touted primarily as a style of relating to patients, literature that
followed its introduction highlighted specific techniques. These techniques were not forward‐
ed as specifically essential to the approach but rather were considered to be naturally emerging
and optimal examples of how the perspective might appear in practice.
4.8. Efficacy of treatment approaches
As has been discussed, various treatment approaches have developed for the treatment of
substance-related disorders. In the interest of brevity, Table 1 is presented with references
pertaining to the nature of the treatment approaches and their efficacy. There are some
important observations that are worth noting beyond the specifics of the table. Evidence
continues to accumulate for the effectiveness of a variety of treatment approaches as well as
the distinct cost advantage that treatment has over incarceration [72]. There is a continued call
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for “translational research” that takes findings from the laboratory and cultivates enhanced
clinical practice [73]. New methods of assessing efficacy have been proposed that are more
ecologically valid than traditional outcome studies, particularly emphasizing longer periods
of follow-up [74].
References  Notes
Evidence-based
approach
[77] Argues for more specific targets in treatment and reviews difficulties in
empirical support for empirically supported treatments
[78] Examines issues associated with the development and use of evidence-
based treatment research
Detoxification [40] An evaluation of the factors that are associated with successful detox
completion
[79] Examined the impact of medically assisted detoxification on subsequent
outcomes
Harm reduction [80] Reviews approaches to and perspectives on the harm reduction approach
[81] Evaluation of syringe dispensing machines and public impact – example of
harm reduction strategy
Relapse prevention [82] Reviews three main approaches to pharmacological intervention for relapse
prevention
[83] Review of the effectiveness of relapse prevention with substance abuse
disorders
Interpersonal therapies [84] Description of practical elements of family therapy approaches to substance
abuse treatment
[85] Review of six articles that considered creative writing as a facilitator of the
interpersonal therapy process
[86] Considers a broad array of approaches to improving the life of a substance
abuser, including expressive therapy, art therapy, spiritual intervention, etc.
[87] Brief discussion of elements of interpersonal intervention with substance
abusers
[37] A discussion of relationship factors in treatment of substance use disorders
Cognitive behavioral and
behavioral therapy
[88] Examined the impact of adding a trauma component to group-based
cognitive behavioral therapy
[57] Outcome study of electronic reminders of goals for group of drug-involved
offenders.
[89] Review of the effectiveness of mindfulness interventions with substance use
disorders
[55] Evaluation of a contingency management program to reduce substance use
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References  Notes
Medication assisted and
physiologic therapy
[90] Report of a review of studies of transcranial magnetic stimulation on
addiction
[62] A review outcome studies of the effectiveness of EEG Biofeedback for
treatment of substance use disorder
[65] Evaluated the use of transcranial magnetic stimulation on smoking cue-
induced craving
[91] Evaluated the use of selective serotonin reuptake inhibitors for substance
use disorders.
Motivational
interviewing (MI)
[92] Discusses the combination of MI with cognitive behavioral
technique
[93] Considered the connection between therapist attitude toward MI and
impact on client interpersonal functioning
Drug court [94] Evaluated drug courts as a promoter of “turning points” for offenders
in areas of self-esteem, relationship, educational development,
employment
[95] Examination of the value of compulsory treatment of addiction in
Australia and the United States
Alcoholics anonymous [96] Considers the value of the “therapeutic alliance” that develops in
AA as a significant curative factor
[97] Examines the effectiveness of AA in a research method that reduces
previous method problems. Support for the effectiveness of AA
is reported.
Table 1. Representative literature of efficacy and application of treatment approaches.
5. Conclusion
The history of use of mood-altering substances is complex and controversial. For centuries, the
conflict between the benefits of varied substances and the massive societal costs of the misuse
of substances has been confused by political and economic motivations for action related to
substance users. A contemporary response to the complexity and cost of substance-related
disorders is the development of the drug court. The first drug court was created in Florida
in 1989 [75] as there was growing awareness of the widespread presence of substance abusing
offenders in the criminal justice system. As testimony to the appeal of the drug court con‐
cept, one may note that National institute of Justice reported that there were more than 3400
drug courts in the United States by the middle of 2014. Drug court programs consider an
individual’s unique patterns of use and associated consequences with a graduated series of
rewards for the attainment of target behaviors. Early evidence suggests that drug courts are
associated with lower recidivism [76]. Drug court may reflect the type of approach that fits the
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complex and destructive influence of substance misuse. Drug court is a program that offers
many services to legally mandated individuals, and it represents an intersection between
several models of addiction, most notably the moral and medical models. Following a legal
adjudication, a treatment and follow-up plan is created that involves the judgment and
leverage intrinsic to the criminal justice system. Thus, the moral dimension of drug court serves
as the “teeth” for the accountability built into the program. At the same time, the nature of the
substance use problem is assessed and diagnosed by treatment facilities that work in concert
with the court. Treatment is based on the prevailing diagnostic system (DSM, ICD) that reflects
the specific diagnostic criteria and decision rules that characterize the medical model. With
this combination of perspectives, the drug court concept may represent the interdisciplinary
future of substance abuse therapeutics.
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